Dr Abou-Alfa speaks with ecancertv at ASCO 2016 about two trials treating hepatocellular carcinoma; a combination therapy of sorafenib and doxorubicin, and ADI-peg20.
Dr Abou-Alfa summarises the background of target determination in both trials, focussing on arginine-citruline synthesis in HCC tumour microenvironment and the history of doxorubicin as a single or combination therapy.
In both trials, the therapies in question did not improve overall survival.
With these results in mind, Dr Abou-alfa discusses future avenues for research.
For more on novel HCC treatments, click here.